Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784614 | PMC |
| http://dx.doi.org/10.1177/2333794X15608800 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Influenza Patients Who Received Ventilator Management During the 2024 to 2025 Major Influenza-Endemic Season in a Tertiary Hospital in Japan.
Int Med Case Rep J
May 2025
Division of Respirology, Tohoku Medical and Pharmaceutical University, Sendai City, Japan.
Three cases of severe influenza that required ventilator management in the 2024-2025 season, which was a major influenza season in Japan, are presented. Case 1: A 54-year-old man with obesity developed lobar pneumonia as a result of severe community-acquired pneumonia (CAP) secondary to methicillin-susceptible (MSSA), as confirmed on sputum culture. The nasal swab was positive for influenza A antigen.
View Article and Find Full Text PDFPreparation and comprehensive preclinical study of Peramivir inhalation solution: Achieving accurate drug delivery.
Biomed Pharmacother
May 2025
Langtian Pharmaceutical (Hubei) Co.,Ltd., Huangshi 435000, China; Department of Pharmacy, Hubei University of Science and Technology, Xianning 437100, China. Electronic address:
Peramivir, a Neuraminidase inhibitor used for influenza A or B treatment, is currently marketed in the form of injections globally. However, Peramivir injections result in widespread systemic distribution, with only 3-9 % of the drug reaching the nasal cavity and pharyngeal mucus (key sites of action). In contrast, inhaled formulations can directly reach the site of absorption or action, leading to rapid onset of effect.
View Article and Find Full Text PDFIn Vitro and In Vivo Assessment of Pharmacokinetic Profile of Peramivir in the Context of Inhalation Therapy.
Pharmaceuticals (Basel)
January 2025
State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Objective: The aim was to evaluate the pharmacokinetics and underlying mechanisms of peramivir, a clinically approved antiviral agent for severe influenza, subsequent to airway inhalation in rats, thereby surmounting the constraints associated with the sole currently available intravenous formulation.
Methods: Pharmacokinetic and tissue distribution investigations of peramivir were carried out in rats following both intravenous and inhaled administration. In vitro cell models were verified to investigate peramivir's transmembrane transport and cellular uptake across diverse cell systems.
Effectiveness of Antiviral Treatment with Intravenous Peramivir and Oral Oseltamivir for Seasonal Influenza in Children.
Children (Basel)
December 2024
Department of Emergency Medicine, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13496, Republic of Korea.
Background/objectives: Influenza poses significant risks in children, causing complications like febrile seizures and hospitalizations. Antiviral treatments include oseltamivir and peramivir, both FDA-approved neuraminidase inhibitors. This study aims to compare the effectiveness of intravenous peramivir and oral oseltamivir in pediatric patients presenting to an emergency department, with a primary focus on the revisit rate within 72 h post-treatment.
View Article and Find Full Text PDFEfficacy of Pharmacotherapy for Seasonal Influenza in Young and Middle-aged Adults: A Systematic Review and Network Meta-analysis.
Intern Med
November 2024
Department of Public Health, Osaka University Graduate School of Medicine, Japan.
Objective Seasonal influenza affects healthcare demand. However, the efficacy of anti-influenza drugs, particularly among young patients at a low risk of complications, has rarely been evaluated. Therefore, we evaluated the efficacy of anti-influenza drugs against seasonal influenza in healthy young and middle-aged adults.
View Article and Find Full Text PDF